Aa
vaccine news
I found this artical to be promising
Roswell Park Clinician Awarded $700,000 Ovarian Cancer Research Grant
BUFFALO, NY – Kunle Odunsi, MD, PhD, Attending Physician in the Division of Gynecologic Oncology, Department of Surgery, at Roswell Park Cancer Institute (RPCI), has been awarded a three-year, $700,000, Cancer Vaccine Collaborative grant from the Cancer Research Institute (CRI) for a study titled, "Antigen Specific Vaccine Therapy for Ovarian Cancer Utilizing NY-ESO-1 as Target."
Ovarian cancer is sometimes referred to as a silent killer because many women are not diagnosed until the disease is in its advanced stages. Existing treatment options have had limited impact on patient survival, with only two of 10 women living more than five years after diagnosis.
Development of a vaccine which targets ovarian cancer antigens may lead to more effective treatment. Until recently, such tumor specific antigens have been difficult to identify, and even when they are found, they do not necessarily elicit strong immune responses sufficient to kill cancer cells.
NY-ESO-1 is one of the most promising ovarian cancer antigens identified to date. Dr. Odunsi will conduct a phase I/II clinical trial to evaluate the dose, toxicity and immunological effectiveness of NY-ESO-1 antigen specific immunotherapy in patients with epithelial ovarian cancer.
"Vaccine development has proven to be one of the most promising and exciting areas of cancer research," noted Dr. Odunsi. "The NY-ESO-1 antigen is expressed in a significant proportion of patients with ovarian cancer and represents an attractive target for immunotherapy."
The Cancer Vaccine Collaborative program is a partnership between CRI and the Ludwig Institute for Cancer Research, which coordinates cancer vaccine trials using defined novel antigens, standardized treatment protocols, uniform monitoring methodologies, and data collection.
The Cancer Research Institute was founded in 1953 to foster the science of cancer immunology, which is based on the premise that the body’s immune system can be mobilized against cancer. For nearly five decades, the Institute has been a sustaining force in cancer immunology research and its mission has been to develop innovative programs that fund gifted scientists and clinicians at preeminent research institutions.
The Ludwig Institute for Cancer Research is an international research group that addresses complex biological problems related to cancer with a critical mass of interactive investigators having expertise in several scientific disciplines.
Roswell Park Cancer Institute, founded in 1898, is the nation’s first cancer research, treatment and education center and is the only National Cancer Institute-designated comprehensive cancer center in Western New York.
Roswell Park Clinician Awarded $700,000 Ovarian Cancer Research Grant
BUFFALO, NY – Kunle Odunsi, MD, PhD, Attending Physician in the Division of Gynecologic Oncology, Department of Surgery, at Roswell Park Cancer Institute (RPCI), has been awarded a three-year, $700,000, Cancer Vaccine Collaborative grant from the Cancer Research Institute (CRI) for a study titled, "Antigen Specific Vaccine Therapy for Ovarian Cancer Utilizing NY-ESO-1 as Target."
Ovarian cancer is sometimes referred to as a silent killer because many women are not diagnosed until the disease is in its advanced stages. Existing treatment options have had limited impact on patient survival, with only two of 10 women living more than five years after diagnosis.
Development of a vaccine which targets ovarian cancer antigens may lead to more effective treatment. Until recently, such tumor specific antigens have been difficult to identify, and even when they are found, they do not necessarily elicit strong immune responses sufficient to kill cancer cells.
NY-ESO-1 is one of the most promising ovarian cancer antigens identified to date. Dr. Odunsi will conduct a phase I/II clinical trial to evaluate the dose, toxicity and immunological effectiveness of NY-ESO-1 antigen specific immunotherapy in patients with epithelial ovarian cancer.
"Vaccine development has proven to be one of the most promising and exciting areas of cancer research," noted Dr. Odunsi. "The NY-ESO-1 antigen is expressed in a significant proportion of patients with ovarian cancer and represents an attractive target for immunotherapy."
The Cancer Vaccine Collaborative program is a partnership between CRI and the Ludwig Institute for Cancer Research, which coordinates cancer vaccine trials using defined novel antigens, standardized treatment protocols, uniform monitoring methodologies, and data collection.
The Cancer Research Institute was founded in 1953 to foster the science of cancer immunology, which is based on the premise that the body’s immune system can be mobilized against cancer. For nearly five decades, the Institute has been a sustaining force in cancer immunology research and its mission has been to develop innovative programs that fund gifted scientists and clinicians at preeminent research institutions.
The Ludwig Institute for Cancer Research is an international research group that addresses complex biological problems related to cancer with a critical mass of interactive investigators having expertise in several scientific disciplines.
Roswell Park Cancer Institute, founded in 1898, is the nation’s first cancer research, treatment and education center and is the only National Cancer Institute-designated comprehensive cancer center in Western New York.
Interesting news. I think these immunotherapy type treatments do seem like a very promising avenue. I have been trying to find out more info about another ovarian cancer vaccine that is currently in Phase III testing. It's called Abagovomab and there is info about it in Wiki if anyone is interested:
http://en.wikipedia.org/wiki/Abagovomab
http://en.wikipedia.org/wiki/Abagovomab
Have an Answer?
You are reading content posted in the Ovarian Cancer Community
Learn how to spot the warning signs of this “silent killer.”
Diet and digestion have more to do with cancer prevention than you may realize
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
